Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H28O11 |
| Molecular Weight | 480.4618 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]5(COC(=O)C4=CC=CC=C4)[C@H]3C[C@]25O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O
InChI
InChIKey=YKRGDOXKVOZESV-WRJNSLSBSA-N
InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1
| Molecular Formula | C23H28O11 |
| Molecular Weight | 480.4618 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26514553
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26514553
Peoniflorin (PF) is the chief active component of paeonia, with diverse pharmacological actions and wide application. According to current study findings, PF can ameliorate the decline of memory and learning capacities in many dementia model animals, and have effect in protecting the cerebral ischemia injury, treating Parkinson's disease, reliving pain and improving neural synapse plasticity. Peoniflorin is an Adenosine A1 receptor activator with neuroprotective and antidepressant effects. Upregulates serotonergic systems in vivo. Blood brain barrier permeable. Preclinical studies show that peoniflorin is able to diminish pain, joint swelling, synovial hypertrophy, and the severity of bone erosion and cartilage degradation in experimental arthritis. In China, Korea, and Japan, a decoction of the dried root without bark of Paeonia lactiflora Pall. has been used in the treatment of rheumatoid arthritis, systemic lupus erythematosus, hepatitis, dysmenorrhea, muscle cramping and spasms, and fever for more than 1200 years. A water/ethanol extract of the root is now known as total glucosides of peony (TGP), which contains more than 15 components. Peoniflorin is the most abundant ingredient and accounts for the pharmacological effects observed with TGP in both in vitro and in vivo studies.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006954 |
|||
Target ID: GO:0051402 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25967667 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| moderate | ||||
| weak | ||||
| weak | ||||
| yes [Inhibition 10 uM] | ||||
| yes [Inhibition 10 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/22040564/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/22040564/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/22040564/ |
yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway. | 2013-04-26 |
|
| Protective effects of paeoniflorin against cobalt chloride-induced apoptosis of endothelial cells via HIF-1α pathway. | 2012-04 |
|
| Role of four major components in the effect of Si-Ni-San, a traditional Chinese prescription, against contact sensitivity in mice. | 2006-09 |
|
| Paeoniflorin reverses guanethidine-induced hypotension via activation of central adenosine A1 receptors in Wistar rats. | 1999-10 |
|
| Effects of paeoniflorin derivatives on scopolamine-induced amnesia using a passive avoidance task in mice; structure-activity relationship. | 1998-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02878863
Peoniflorin tablets (600mg, tid) combination of phosphatidylcholine or silymarin
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25661317
Peoniflorin (10 nmol/L to 1 umol/L) increased the survival of cultured rat cortical neurons subjected to OGD/R. Peoniflorin increased the phosphorylation of Akt and ERK1/2 in these neurons. Peoniflorin (100 nmol/L) treatment of HEK293/A1R cells for 5 min enhanced the co-localization of A1R and EGFR on the cell surface.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:17:25 GMT 2025
by
admin
on
Mon Mar 31 18:17:25 GMT 2025
|
| Record UNII |
21AIQ4EV64
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
3250 (Number of products:2)
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
178886
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
245-476-2
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
DTXSID2042648
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
PAEONIFLORIN
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
442534
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
1491616
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
2288155
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
21AIQ4EV64
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
21AIQ4EV64
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY | |||
|
23180-57-6
Created by
admin on Mon Mar 31 18:17:25 GMT 2025 , Edited by admin on Mon Mar 31 18:17:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
CONSTITUENT ALWAYS PRESENT -> PARENT |
Compound tested and showed no antiproliferative effects against two human cancer cell lines, OVCA 429 ovarian cancer cells and BT 483 breast cancer cells (IC50 N 100 μM) by MTT assay.
|
||
|
CONSTITUENT ALWAYS PRESENT -> PARENT |
26.5 ? 3.9% neuroprotective activity of compound against 10.0 uM H2O2-induced neurotoxicity in primary cultures of rat cortical cells.
|
||
|
CONSTITUENT ALWAYS PRESENT -> PARENT | |||
|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
CONSTITUENT ALWAYS PRESENT -> PARENT |
Effect of PL, paeoniflorin and paeonol on degranulation of rat peritoneal mast cells (IC50 = >100 uM) and RBL-2H3 (IC50 = >100 uM) cells.
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Compound was tested for anticomplement activity through the Classical Pathway (CP) and Alternative Pathway (AP).
|
||
|
CONSTITUENT ALWAYS PRESENT -> PARENT |